Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1983 2
1984 5
1985 2
1986 2
1989 1
1991 1
1992 2
1993 5
1994 4
1995 2
1996 1
1997 4
1998 3
1999 8
2000 7
2001 13
2002 9
2003 17
2004 15
2005 17
2006 17
2007 24
2008 31
2009 28
2010 27
2011 23
2012 17
2013 20
2014 24
2015 15
2016 32
2017 28
2018 28
2019 30
2020 27
2021 22
2022 28
2023 26
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Results by year

Filters applied: . Clear all
Page 1
Lithium: A therapeutic option in Alzheimer's disease and its prodromal stages?
Haussmann R, Noppes F, Brandt MD, Bauer M, Donix M. Haussmann R, et al. Neurosci Lett. 2021 Aug 24;760:136044. doi: 10.1016/j.neulet.2021.136044. Epub 2021 Jun 10. Neurosci Lett. 2021. PMID: 34119602 Review.
Clinical studies show procognitive effects in lithium-treated patients with amnestic MCI and Alzheimer's disease. These procognitive effects are associated with changes of CSF biomarkers of Alzheimer's disease. After 3 months of …
Clinical studies show procognitive effects in lithium-treated patients with amnestic MCI and Alzheimer's disease …
Lithium, a Treatment Option for Alzheimer's Disease? A Review of Existing Evidence and Discussion on Future Perspectives.
Guilliot S, Gauthier S, Touchon J, Soto ME. Guilliot S, et al. J Alzheimers Dis. 2023;96(2):473-482. doi: 10.3233/JAD-230568. J Alzheimers Dis. 2023. PMID: 37781804 Review.
Throughout this period, the potential for lithium salts has been extensively studied and numerous data favor its use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD). We reviewed existing evidence gathered from clinical …
Throughout this period, the potential for lithium salts has been extensively studied and numerous data favor its use in the treatment …
Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium.
Singulani MP, De Paula VJR, Forlenza OV. Singulani MP, et al. Neurosci Lett. 2021 Aug 24;760:136078. doi: 10.1016/j.neulet.2021.136078. Epub 2021 Jun 20. Neurosci Lett. 2021. PMID: 34161823 Review.
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by the accumulation of abnormal tau proteins within neurons and amyloid plaques in the brain parenchyma, which leads to progressive loss of neurons in the brain. W …
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by the accumulation of …
Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.
Wei HF, Anchipolovsky S, Vera R, Liang G, Chuang DM. Wei HF, et al. Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):2201-2214. doi: 10.26355/eurrev_202203_28369. Eur Rev Med Pharmacol Sci. 2022. PMID: 35363371 Free PMC article. Review.
Disruption of intracellular Ca2+ homeostasis plays an important role as an upstream pathology in Alzheimer's disease (AD), and correction of Ca2+ dysregulation has been increasingly proposed as a target of future effective disease-modified drugs for tr …
Disruption of intracellular Ca2+ homeostasis plays an important role as an upstream pathology in Alzheimer's disease (A …
Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective.
Hampel H, Lista S, Mango D, Nisticò R, Perry G, Avila J, Hernandez F, Geerts H, Vergallo A; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. J Alzheimers Dis. 2019;69(3):615-629. doi: 10.3233/JAD-190197. J Alzheimers Dis. 2019. PMID: 31156173 Review.
Systems pharmacology is a novel framework for drug research that models traditional and innovative pharmacological parameters and provides the overall efficacy and safety profile of a drug across body systems and complex, non-linear, molecular interactions. Lithium chlorid …
Systems pharmacology is a novel framework for drug research that models traditional and innovative pharmacological parameters and provides t …
Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer's Disease and Related Dementia.
Shim SS, Berglund K, Yu SP. Shim SS, et al. Neurodegener Dis. 2023;23(1-2):1-12. doi: 10.1159/000533797. Epub 2023 Sep 4. Neurodegener Dis. 2023. PMID: 37666228 Review.
BACKGROUND: Although Alzheimer's disease (AD) is the most common form of dementia, the effective treatment of AD is not available currently. ...Through these therapeutic actions, lithium produces therapeutic effects on AD with potential to modify the …
BACKGROUND: Although Alzheimer's disease (AD) is the most common form of dementia, the effective treatment of AD is not …
Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N. Matsunaga S, et al. J Alzheimers Dis. 2015;48(2):403-10. doi: 10.3233/JAD-150437. J Alzheimers Dis. 2015. PMID: 26402004 Review.
BACKGROUND: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). METHODS: The primary outcome measure was …
BACKGROUND: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with …
Beyond its Psychiatric Use: The Benefits of Low-dose Lithium Supplementation.
Hamstra SI, Roy BD, Tiidus P, MacNeil AJ, Klentrou P, MacPherson REK, Fajardo VA. Hamstra SI, et al. Curr Neuropharmacol. 2023;21(4):891-910. doi: 10.2174/1570159X20666220302151224. Curr Neuropharmacol. 2023. PMID: 35236261 Free PMC article. Review.
This review summarizes these findings with a focus on low-dose lithium's potential benefits on the aging process and age-related diseases of these systems, such as cardiovascular disease, osteoporosis, sarcopenia, obesity and type 2 diabetes, Alzheimer …
This review summarizes these findings with a focus on low-dose lithium's potential benefits on the aging process and age-relat …
Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model.
Wiseman AL, Briggs CA, Peritt A, Kapecki N, Peterson DA, Shim SS, Stutzmann GE. Wiseman AL, et al. J Alzheimers Dis. 2023;91(1):273-290. doi: 10.3233/JAD-220758. J Alzheimers Dis. 2023. PMID: 36442195
BACKGROUND: Alzheimer's disease (AD) is a chronic neurodegenerative disorder with a progressive loss of cognitive function. ...Lithium could serve as an effective treatment or co-therapeutic for AD....
BACKGROUND: Alzheimer's disease (AD) is a chronic neurodegenerative disorder with a progressive loss of cognitive funct …
Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Honyashiki M, Inoue T. Terao I, et al. Ageing Res Rev. 2022 Nov;81:101709. doi: 10.1016/j.arr.2022.101709. Epub 2022 Aug 9. Ageing Res Rev. 2022. PMID: 35961514 Review.
BACKGROUND: In 2021, the US Food and Drug Administration granted an accelerated approval to aducanumab for patients with mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease (AD); however, the cost of aducanumab is high, at approxim …
BACKGROUND: In 2021, the US Food and Drug Administration granted an accelerated approval to aducanumab for patients with mild cognitive impa …
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Kodama W. Terao I, et al. Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20. Ageing Res Rev. 2024. PMID: 38253184 Review.
BACKGROUND: The comparative clinical utility of the disease-modifying treatments for mild cognitive impairment and Alzheimer's disease that are approved or under review by the Food and Drug Administration (i.e., donanemab, lecanemab and aducanumab), an …
BACKGROUND: The comparative clinical utility of the disease-modifying treatments for mild cognitive impairment and Alzheimer' …
The Putative Use of Lithium in Alzheimer's Disease.
Morris G, Berk M. Morris G, et al. Curr Alzheimer Res. 2016;13(8):853-61. doi: 10.2174/1567205013666160219113112. Curr Alzheimer Res. 2016. PMID: 26892287 Review.
Alzheimer`s disease is a progressive neurodegenerative illness characterized by the invariant existence of beta-amyloid plaques and neurofibrillary tangles. ...Data regarding efficacy in human trials and animal models of AD are mixed, but recent data using "m …
Alzheimer`s disease is a progressive neurodegenerative illness characterized by the invariant existence of beta-amyloid …
Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy.
Damri O, Shemesh N, Agam G. Damri O, et al. Int J Mol Sci. 2020 Dec 27;22(1):189. doi: 10.3390/ijms22010189. Int J Mol Sci. 2020. PMID: 33375448 Free PMC article. Review.
Lithium's neuroprotective properties rely on its modulation of homeostatic mechanisms such as inflammation, mitochondrial function, oxidative stress, autophagy, and apoptosis. This myriad of intracellular responses are, possibly, consequences of the drug's inhibitio …
Lithium's neuroprotective properties rely on its modulation of homeostatic mechanisms such as inflammation, mitochondrial func …
Does lithium prevent Alzheimer's disease?
Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Forlenza OV, et al. Drugs Aging. 2012 May 1;29(5):335-42. doi: 10.2165/11599180-000000000-00000. Drugs Aging. 2012. PMID: 22500970 Review.
Recent studies addressing the inhibition of glycogen synthase kinase-3 beta (GSK3B) by lithium have further suggested the modification of biological cascades that pertain to the pathophysiology of Alzheimer's disease (AD). ...Therefore, lithium …
Recent studies addressing the inhibition of glycogen synthase kinase-3 beta (GSK3B) by lithium have further suggested the modificatio …
GSK3 and tau: two convergence points in Alzheimer's disease.
Hernandez F, Lucas JJ, Avila J. Hernandez F, et al. J Alzheimers Dis. 2013;33 Suppl 1:S141-4. doi: 10.3233/JAD-2012-129025. J Alzheimers Dis. 2013. PMID: 22710914 Free article. Review.
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that plays a key role in the pathogenesis of Alzheimer's disease (AD). GSK3 phosphorylates tau in most serine and threonine residues hyperphosphorylated in paired helical fi …
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that plays a key role in the pathogenesis of Alzhei …
Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease.
Singulani MP, Ferreira AFF, Figueroa PS, Cuyul-Vásquez I, Talib LL, Britto LR, Forlenza OV. Singulani MP, et al. Ageing Res Rev. 2024 Mar;95:102231. doi: 10.1016/j.arr.2024.102231. Epub 2024 Feb 15. Ageing Res Rev. 2024. PMID: 38364914 Review.
We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium in Alzheimer's (AD) and Parkinson's disease (PD). We followed the PRISMA guidelines and performed the systematic litera …
We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium …
Lithium: a novel treatment for Alzheimer's disease?
Zhong J, Lee WH. Zhong J, et al. Expert Opin Drug Saf. 2007 Jul;6(4):375-83. doi: 10.1517/14740338.6.4.375. Expert Opin Drug Saf. 2007. PMID: 17688381 Review.
One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower tau and beta-amyloid levels in cerebrospinal fluid in Alzheimer's patients. This re …
One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating …
Autophagy and Tau Protein.
Hamano T, Enomoto S, Shirafuji N, Ikawa M, Yamamura O, Yen SH, Nakamoto Y. Hamano T, et al. Int J Mol Sci. 2021 Jul 12;22(14):7475. doi: 10.3390/ijms22147475. Int J Mol Sci. 2021. PMID: 34299093 Free PMC article. Review.
Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer's disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. ...Thus far, as au …
Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzhe …
Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation.
Deliyannides DA, Graff JA, Niño I, Lee S, Husain MM, Forester BP, Crocco E, Vahia IV, Devanand DP. Deliyannides DA, et al. Int J Geriatr Psychiatry. 2023 Sep;38(9):e6002. doi: 10.1002/gps.6002. Int J Geriatr Psychiatry. 2023. PMID: 37732619 Clinical Trial.
Little is known, however, about the effects of lithium on BDNF in Alzheimer's Dementia (AD). In one study of patients with Mild Cognitive Impairment, serum BDNF increased after treatment with lithium. These patients also showed mild improvement in cogn …
Little is known, however, about the effects of lithium on BDNF in Alzheimer's Dementia (AD). In one study of patients w …
Psychosis in Alzheimer's Disease.
Ballard C, Kales HC, Lyketsos C, Aarsland D, Creese B, Mills R, Williams H, Sweet RA. Ballard C, et al. Curr Neurol Neurosci Rep. 2020 Oct 13;20(12):57. doi: 10.1007/s11910-020-01074-y. Curr Neurol Neurosci Rep. 2020. PMID: 33048274 Free PMC article. Review.
PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer's disease (AD). RECENT FINDINGS: Psychosis in Alzheimer's disease (AD) has an incidence of ~ 10% …
PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzhei …
The Present State of Lithium for the Prevention of Dementia Related to Alzheimer's Dementia in Clinical and Epidemiological Studies: A Critical Review.
Ishii N, Terao T, Hirakawa H. Ishii N, et al. Int J Environ Res Public Health. 2021 Jul 22;18(15):7756. doi: 10.3390/ijerph18157756. Int J Environ Res Public Health. 2021. PMID: 34360049 Free PMC article. Review.
Moreover, of three good epidemiological studies on trace lithium levels, two supported the aforementioned effects of lithium. The number of studies were substantially small, particularly those on trace lithium levels. Moreover, studies on standard lithium …
Moreover, of three good epidemiological studies on trace lithium levels, two supported the aforementioned effects of lithium. …
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
Forlenza OV, De-Paula VJ, Diniz BS. Forlenza OV, et al. ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6. ACS Chem Neurosci. 2014. PMID: 24766396 Free PMC article. Review.
Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression. More recently, based on findings from translational research, lithium has also been regarded as a neuroprotective agent and a candidate …
Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression. Mor …
Lithium, a potential protective drug in Alzheimer's disease.
Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, Hernández F, Avila J. Engel T, et al. Neurodegener Dis. 2008;5(3-4):247-9. doi: 10.1159/000113715. Epub 2008 Mar 6. Neurodegener Dis. 2008. PMID: 18322403 Review.
Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. ...Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like …
Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques a …
A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity.
Wen J, Sawmiller D, Wheeldon B, Tan J. Wen J, et al. CNS Neurol Disord Drug Targets. 2019;18(10):769-778. doi: 10.2174/1871527318666191114095249. CNS Neurol Disord Drug Targets. 2019. PMID: 31724518 Review.
Recent studies have also shown that it has the potential for the treatment of many other neurodegenerative disorders, including Alzheimer's, Parkinson's and Huntington's disease, through its neurotrophic, neuroprotective, antioxidant and anti-inflammatory act …
Recent studies have also shown that it has the potential for the treatment of many other neurodegenerative disorders, including Alzheimer …
Lithium in drinking water and Alzheimer's dementia: Epidemiological Findings from National Data Base of Japan.
Muronaga M, Terao T, Kohno K, Hirakawa H, Izumi T, Etoh M. Muronaga M, et al. Bipolar Disord. 2022 Dec;24(8):788-794. doi: 10.1111/bdi.13257. Epub 2022 Sep 13. Bipolar Disord. 2022. PMID: 36073313
OBJECTIVES: The aim of this study was to investigate the association between lithium levels in drinking water and prevalence of Alzheimer's dementia (AD). ...RESULTS: The adjusted model showed a significant inverse association of lithium levels with fe …
OBJECTIVES: The aim of this study was to investigate the association between lithium levels in drinking water and prevalence of Al …
Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.
Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, Ballard C. Ismail Z, et al. Nat Rev Neurol. 2022 Mar;18(3):131-144. doi: 10.1038/s41582-021-00597-3. Epub 2022 Jan 4. Nat Rev Neurol. 2022. PMID: 34983978 Free PMC article. Review.
Psychosis is a common and distressing symptom in people with Alzheimer disease, and few safe and effective treatments are available. ...New nosological perspectives have been provided by incorporating the emergence of psychotic symptoms in older adults - even in adv …
Psychosis is a common and distressing symptom in people with Alzheimer disease, and few safe and effective treatments are avai …
Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.
Devanand DP, Crocco E, Forester BP, Husain MM, Lee S, Vahia IV, Andrews H, Simon-Pearson L, Imran N, Luca L, Huey ED, Deliyannides DA, Pelton GH. Devanand DP, et al. Am J Geriatr Psychiatry. 2022 Jan;30(1):32-42. doi: 10.1016/j.jagp.2021.04.014. Epub 2021 May 12. Am J Geriatr Psychiatry. 2022. PMID: 34059401 Free PMC article. Clinical Trial.
OBJECTIVES: To evaluate low-dose lithium treatment of agitation in Alzheimer's disease (AD). METHOD: In a four-site trial, patients with AD and agitation/aggression score 4 on the Neuropsychiatric Inventory (NPI) were randomized, double-blind, to li …
OBJECTIVES: To evaluate low-dose lithium treatment of agitation in Alzheimer's disease (AD). METHOD: In a four-s …
Association Between Lithium Use and Risk of Alzheimer's Disease.
Cheng C, Zandi P, Stuart E, Lin CH, Su PY, Alexander GC, Lan TH. Cheng C, et al. J Clin Psychiatry. 2017 Feb;78(2):e139-e145. doi: 10.4088/JCP.15m10304. J Clin Psychiatry. 2017. PMID: 28002662
OBJECTIVE: Current evidence for the association between use of lithium and risk of dementia is mixed. The objective of this study was to assess the risk of Alzheimer's disease associated with use of lithium. ...The adjusted odds ratio (aOR) of …
OBJECTIVE: Current evidence for the association between use of lithium and risk of dementia is mixed. The objective of this study was …
Clinical Perspectives of Lithium's Neuroprotective Effect.
Rybakowski JK, Suwalska A, Hajek T. Rybakowski JK, et al. Pharmacopsychiatry. 2018 Sep;51(5):194-199. doi: 10.1055/s-0043-124436. Epub 2017 Dec 21. Pharmacopsychiatry. 2018. PMID: 29270949 Review.
It has been reflected by an increase in cerebral gray matter volume in lithium-treated subjects and by the favorable influence of lithium on cognitive functions. ...Data from experimental, epidemiological, and clinical studies have also pointed to an antidementia ef …
It has been reflected by an increase in cerebral gray matter volume in lithium-treated subjects and by the favorable influence of …
Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium.
Priebe GA, Kanzawa MM. Priebe GA, et al. Med Hypotheses. 2020 Apr;137:109573. doi: 10.1016/j.mehy.2020.109573. Epub 2020 Jan 20. Med Hypotheses. 2020. PMID: 31986471
Alzheimer's disease (AD) is a pervasive and progressive neurodegenerative disorder characterized by a gradual decline in memory, leading to significant impairments in cognition, language, and social functioning. ...After a thorough review of the literature an …
Alzheimer's disease (AD) is a pervasive and progressive neurodegenerative disorder characterized by a gradual decline i …
Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder.
Hu W, Zhao M, Lian J, Li D, Wen J, Tan J. Hu W, et al. CNS Neurol Disord Drug Targets. 2022 Aug 25. doi: 10.2174/1871527321666220825114236. Online ahead of print. CNS Neurol Disord Drug Targets. 2022. PMID: 36028968
BACKGROUND AND OBJECTIVE: Recent studies have shown that lithium treatment can reduce symptoms of Alzheimer's disease (AD) and Autism Spectrum Disorder (ASD). ...Consequently, there is a demand for a safer and more effective lithium formulation …
BACKGROUND AND OBJECTIVE: Recent studies have shown that lithium treatment can reduce symptoms of Alzheimer's diseas …
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Majidazar R, Rezazadeh-Gavgani E, Sadigh-Eteghad S, Naseri A. Majidazar R, et al. Eur J Clin Pharmacol. 2022 Oct;78(10):1567-1587. doi: 10.1007/s00228-022-03363-6. Epub 2022 Jul 26. Eur J Clin Pharmacol. 2022. PMID: 35881170 Review.
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of dementia. ...These studies assessed effects of immunotherapy, cholinesterase inhibitors (ChEIs), memantine, statins, lithium, nonsteroidal anti-infl …
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of dementia. ...Th …
Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, Vahia IV, Andrews H, Wall MM, Pelton GH. Devanand DP, et al. Contemp Clin Trials. 2018 Aug;71:33-39. doi: 10.1016/j.cct.2018.05.019. Epub 2018 May 31. Contemp Clin Trials. 2018. PMID: 29859917 Free PMC article. Clinical Trial.
Symptoms of agitation, aggression, and psychosis frequently occur in patients with Alzheimer's disease (AD). These symptoms are distressing to patients and caregivers, often lead to institutionalization, are associated with increased mortality, and are very d …
Symptoms of agitation, aggression, and psychosis frequently occur in patients with Alzheimer's disease (AD). These symp …
Lithium therapy's potential to lower dementia risk and the prevalence of Alzheimer's disease: a meta-analysis.
Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q. Lu Q, et al. Eur Neurol. 2024 Apr 24. doi: 10.1159/000538846. Online ahead of print. Eur Neurol. 2024. PMID: 38657568
INTRODUCTION: Dementia is a neurodegenerative disease with insidious onset and progressive progression, of which the most common type is Alzheimer's disease (AD). ...METHODS: A systematic literature review was conducted in PubMed, Embase, and Web of Sc …
INTRODUCTION: Dementia is a neurodegenerative disease with insidious onset and progressive progression, of which the most common type …
Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease.
Alvarez G, Muñoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, Díaz-Nido J. Alvarez G, et al. Bipolar Disord. 2002 Jun;4(3):153-65. doi: 10.1034/j.1399-5618.2002.01150.x. Bipolar Disord. 2002. PMID: 12180271 Review.
Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of the beta-amyloid peptide and the hyperphosphorylation of the tau protein, among other features. ...In our opinion, the possibility of using lithium, or other inhib …
Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of the beta-amyloid peptide and t …
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H. Hampel H, et al. J Clin Psychiatry. 2009 Jun;70(6):922-31. J Clin Psychiatry. 2009. PMID: 19573486 Clinical Trial.
Since hyperphosphorylation of tau is a core pathological feature in Alzheimer's disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in Alzheimer's disease. In the current study, we tested the effect o …
Since hyperphosphorylation of tau is a core pathological feature in Alzheimer's disease, lithium-induced inhibit …
Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer's Disease.
Gherardelli C, Cisternas P, Inestrosa NC. Gherardelli C, et al. Int J Mol Sci. 2022 Aug 5;23(15):8733. doi: 10.3390/ijms23158733. Int J Mol Sci. 2022. PMID: 35955868 Free PMC article.
Impaired cerebral glucose metabolism is an early event that contributes to the pathogenesis of Alzheimer's disease (AD). Importantly, restoring glucose availability by pharmacological agents or genetic manipulation has been shown to protect against Abeta toxi …
Impaired cerebral glucose metabolism is an early event that contributes to the pathogenesis of Alzheimer's disease (AD) …
Lithium and autophagy.
Motoi Y, Shimada K, Ishiguro K, Hattori N. Motoi Y, et al. ACS Chem Neurosci. 2014 Jun 18;5(6):434-42. doi: 10.1021/cn500056q. Epub 2014 Apr 30. ACS Chem Neurosci. 2014. PMID: 24738557 Free PMC article. Review.
In neurodegenerative diseases, lithium enhances degradation of aggregate-prone proteins, including mutated huntingtin, phosphorylated tau, and alpha-synuclein, and causes damaged mitochondria to degrade, while in a mouse model of cerebral ischemia and Alzheimer's …
In neurodegenerative diseases, lithium enhances degradation of aggregate-prone proteins, including mutated huntingtin, phosphorylated …
Wnt/beta-catenin signaling in Alzheimer's disease.
De Ferrari GV, Avila ME, Medina MA, Perez-Palma E, Bustos BI, Alarcon MA. De Ferrari GV, et al. CNS Neurol Disord Drug Targets. 2014;13(5):745-54. doi: 10.2174/1871527312666131223113900. CNS Neurol Disord Drug Targets. 2014. PMID: 24365184 Review.
Alzheimer's disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes such as memory, judgment and reasoning. ...We conclude that several components of the cascade are actively engaged in the events leading to …
Alzheimer's disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes …
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder.
Nunes PV, Forlenza OV, Gattaz WF. Nunes PV, et al. Br J Psychiatry. 2007 Apr;190:359-60. doi: 10.1192/bjp.bp.106.029868. Br J Psychiatry. 2007. PMID: 17401045
The prevalence of dementia in the whole sample was 19% v. 7% in an age-comparable population. Alzheimer's disease was diagnosed in 3 patients (5%) on lithium and in 16 patients (33%) who were not on lithium (P<0.001). ...This is in accordance …
The prevalence of dementia in the whole sample was 19% v. 7% in an age-comparable population. Alzheimer's disease was d …
Cytomegalovirus infection induces Alzheimer's disease-associated alterations in tau.
Mody PH, Marvin KN, Hynds DL, Hanson LK. Mody PH, et al. J Neurovirol. 2023 Aug;29(4):400-415. doi: 10.1007/s13365-022-01109-9. Epub 2023 Jul 12. J Neurovirol. 2023. PMID: 37436577
Alzheimer's disease (AD) manifests with loss of neurons correlated with intercellular deposition of amyloid (amyloid plaques) and intracellular neurofibrillary tangles of hyperphosphorylated tau. ...Glycogen synthase kinase 3 beta (GSK3beta) was upregulated i …
Alzheimer's disease (AD) manifests with loss of neurons correlated with intercellular deposition of amyloid (amyloid pl …
Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types.
Fessel J. Fessel J. J Clin Med. 2023 Mar 4;12(5):2049. doi: 10.3390/jcm12052049. J Clin Med. 2023. PMID: 36902833 Free PMC article.
Multiple genetic, metabolic, and environmental abnormalities are known to contribute to the pathogenesis of Alzheimer's dementia (AD). If all of those abnormalities were addressed it should be possible to reverse the dementia; however, that would require a suffocati …
Multiple genetic, metabolic, and environmental abnormalities are known to contribute to the pathogenesis of Alzheimer's dement …
[Lithium and its protective effect in Alzheimer's disease].
Wittenberg SM, Toxopeus KA, Schulte PFJ. Wittenberg SM, et al. Tijdschr Psychiatr. 2017;59(9):559-563. Tijdschr Psychiatr. 2017. PMID: 28880358 Free article. Dutch.
Lithium is associated with adverse effects on cognitive functioning. ...<br/> CONCLUSION: The reported results indicate that the cognitive functioning of patients with pre-stage Alzheimer's disease remains more stable after patients have taken …
Lithium is associated with adverse effects on cognitive functioning. ...<br/> CONCLUSION: The reported results indicate that th …
Beneficial effects of low-dose lithium on cognitive ability and pathological alteration of Alzheimer's disease transgenic mice model.
Liu M, Qian T, Zhou W, Tao X, Sang S, Zhao L. Liu M, et al. Neuroreport. 2020 Sep 9;31(13):943-951. doi: 10.1097/WNR.0000000000001499. Neuroreport. 2020. PMID: 32639272
Lithium has been shown to delay the progression of Alzheimer's disease to reduce the prevalence of dementia. ...Pathologically, it also reduced beta-amyloid plague and p-tau levels. Therefore, our results show that long-term low-dose lithium can …
Lithium has been shown to delay the progression of Alzheimer's disease to reduce the prevalence of dementia. ... …
Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons.
Muñoz-Montaño JR, Moreno FJ, Avila J, Diaz-Nido J. Muñoz-Montaño JR, et al. FEBS Lett. 1997 Jul 14;411(2-3):183-8. doi: 10.1016/s0014-5793(97)00688-1. FEBS Lett. 1997. PMID: 9271202 Free article.
In Alzheimer's disease, tau protein becomes hyperphosporylated, which can contribute to neuronal degeneration. ...These data raise the possibility of using lithium to prevent tau hyperphosphorylation in Alzheimer's disease....
In Alzheimer's disease, tau protein becomes hyperphosporylated, which can contribute to neuronal degeneration. ...These …
Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice.
Habib A, Shytle RD, Sawmiller D, Koilraj S, Munna SA, Rongo D, Hou H, Borlongan CV, Currier G, Tan J. Habib A, et al. J Neurosci Res. 2019 Sep;97(9):1066-1080. doi: 10.1002/jnr.24438. Epub 2019 May 17. J Neurosci Res. 2019. PMID: 31102295 Free PMC article.
Alzheimer's disease (AD) is characterized by progressive decline of cognition and associated neuropsychiatric signs including weight loss, anxiety, depression, agitation, and aggression, which is particularly pronounced in the female gender. Previously, we ha …
Alzheimer's disease (AD) is characterized by progressive decline of cognition and associated neuropsychiatric signs inc …
Neuronal-Glial Interaction in a Triple-Transgenic Mouse Model of Alzheimer's Disease: Gene Ontology and Lithium Pathways.
Rocha NKR, Themoteo R, Brentani H, Forlenza OV, De Paula VJR. Rocha NKR, et al. Front Neurosci. 2020 Dec 1;14:579984. doi: 10.3389/fnins.2020.579984. eCollection 2020. Front Neurosci. 2020. PMID: 33335468 Free PMC article.
Abnormalities in neuronal-glial interactions have been reported in the pathophysiology of Alzheimer's disease (AD), where lithium has been shown to exert neuroprotective effects, including the up-regulation of cytoprotective proteins. In the present st …
Abnormalities in neuronal-glial interactions have been reported in the pathophysiology of Alzheimer's disease (AD), whe …
Evolving therapeutic interventions for the management and treatment of Alzheimer's disease.
Ahmad F, Karan A, Sharma R, Sharma NS, Sundar V, Jayaraj R, Mukherjee S, DeCoster MA. Ahmad F, et al. Ageing Res Rev. 2024 Mar;95:102229. doi: 10.1016/j.arr.2024.102229. Epub 2024 Feb 15. Ageing Res Rev. 2024. PMID: 38364913 Review.
Alzheimer's Disease (AD) patients experience diverse symptoms, including memory loss, cognitive impairment, behavioral abnormalities, mood changes, and mental issues. ...Additionally, we discuss some off-labeled drugs like non-steroidal anti-inflammatory drug …
Alzheimer's Disease (AD) patients experience diverse symptoms, including memory loss, cognitive impairment, behavioral …
Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
Herrmann N, Wang HJ, Song BX, Bawa KK, Lanctôt KL. Herrmann N, et al. Expert Opin Drug Saf. 2022 Oct;21(10):1289-1301. doi: 10.1080/14740338.2022.2136162. Epub 2022 Oct 20. Expert Opin Drug Saf. 2022. PMID: 36252087 Review.
INTRODUCTION: At present, no pharmacological interventions have been approved for the treatment of agitation in Alzheimer's disease (AD), an important neuropsychiatric symptom that has been linked to increased mortality and greater caregiver burden. ...AREAS …
INTRODUCTION: At present, no pharmacological interventions have been approved for the treatment of agitation in Alzheimer's …
Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease - a merging of hypotheses.
Wallace J. Wallace J. Cell Calcium. 2014 Mar;55(3):175-81. doi: 10.1016/j.ceca.2014.02.005. Epub 2014 Feb 22. Cell Calcium. 2014. PMID: 24636273
Intracellular Ca(2+) concentrations are tightly regulated, and elevated levels sustained over periods of time can cause cellular deterioration. The putative role of dysregulated intracellular Ca(2+) in Alzheimer's disease had led to the hypothesis that contro …
Intracellular Ca(2+) concentrations are tightly regulated, and elevated levels sustained over periods of time can cause cellular deteriorati …
Lithium for prevention of Alzheimer's disease.
Terao T. Terao T. Br J Psychiatry. 2007 Oct;191:361; author reply 361-2. doi: 10.1192/bjp.191.4.361. Br J Psychiatry. 2007. PMID: 17906258 No abstract available.
Alzheimer's Disease and Its Potential Alternative Therapeutics.
Kisby B, Jarrell JT, Agar ME, Cohen DS, Rosin ER, Cahill CM, Rogers JT, Huang X. Kisby B, et al. J Alzheimers Dis Parkinsonism. 2019;9(5):477. doi: 10.4172/2161-0460.1000477. Epub 2019 Sep 13. J Alzheimers Dis Parkinsonism. 2019. PMID: 31588368 Free PMC article.
Alzheimer's Disease (AD) is a chronic neurodegenerative disease that affects over 5 million individuals in the United States alone. ...These drugs include: Paroxetine, Desferrioxamine (DFO), N-acetylcysteine (NAC), Posiphen/-(-)Phenserine, JTR-009, Car …
Alzheimer's Disease (AD) is a chronic neurodegenerative disease that affects over 5 million individuals in the U …
What is the Role of Lithium in Epilepsy?
Bojja SL, Singh N, Kolathur KK, Rao CM. Bojja SL, et al. Curr Neuropharmacol. 2022;20(10):1850-1864. doi: 10.2174/1570159X20666220411081728. Curr Neuropharmacol. 2022. PMID: 35410603 Free PMC article. Review.
Lithium is a well-known FDA-approved treatment for bipolar and mood disorders. ...Recent studies highlight the neuroprotective and neurotrophic actions of lithium in amyotrophic lateral sclerosis, Alzheimer's disease, intracerebral hemorrhage, a …
Lithium is a well-known FDA-approved treatment for bipolar and mood disorders. ...Recent studies highlight the neuroprotective and ne …
A feasibility and tolerability study of lithium in Alzheimer's disease.
Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. Macdonald A, et al. Int J Geriatr Psychiatry. 2008 Jul;23(7):704-11. doi: 10.1002/gps.1964. Int J Geriatr Psychiatry. 2008. PMID: 18181229 Clinical Trial.
OBJECTIVE: To assess the safety and feasibility of prescribing long term lithium to elderly people with mild to moderate Alzheimer's disease (AD). ...Nonetheless discontinuation rates are high. The use of lithium as a potential disease mo …
OBJECTIVE: To assess the safety and feasibility of prescribing long term lithium to elderly people with mild to moderate Alzheimer …
Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.
Lauterbach EC. Lauterbach EC. Neural Regen Res. 2016 Nov;11(11):1712-1726. doi: 10.4103/1673-5374.194708. Neural Regen Res. 2016. PMID: 28123400 Free PMC article. Review.
The quest for neuroprotective drugs to slow the progression of neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), has been largely unrewarding. Preclinical evidence sug …
The quest for neuroprotective drugs to slow the progression of neurodegenerative diseases (NDDs), including Alzheimer's dis …
Neuroprotective effects of riluzole in Alzheimer's disease: A comprehensive review.
Golmohammadi M, Mahmoudian M, Hasan EK, Alshahrani SH, Romero-Parra RM, Malviya J, Hjazi A, Najm MAA, Almulla AF, Zamanian MY, Kadkhodaei M, Mousavi N. Golmohammadi M, et al. Fundam Clin Pharmacol. 2024 Apr;38(2):225-237. doi: 10.1111/fcp.12955. Epub 2023 Sep 27. Fundam Clin Pharmacol. 2024. PMID: 37753585 Review.
BACKGROUND: Despite several hundred clinical trials of drugs that initially showed promise, there has been limited clinical improvement in Alzheimer's disease (AD). This may be attributed to the existence of at least 25 abnormal cellular pathways that underli …
BACKGROUND: Despite several hundred clinical trials of drugs that initially showed promise, there has been limited clinical improvement in …
GSK-3 inhibitors for Alzheimer's disease.
Avila J, Hernández F. Avila J, et al. Expert Rev Neurother. 2007 Nov;7(11):1527-33. doi: 10.1586/14737175.7.11.1527. Expert Rev Neurother. 2007. PMID: 17997701 Review.
Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques made of beta-amyloid and the intracellular neurofibrillary tangles made of hyperphosphorylated …
Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's d …
Lithium suppresses Abeta pathology by inhibiting translation in an adult Drosophila model of Alzheimer's disease.
Sofola-Adesakin O, Castillo-Quan JI, Rallis C, Tain LS, Bjedov I, Rogers I, Li L, Martinez P, Khericha M, Cabecinha M, Bähler J, Partridge L. Sofola-Adesakin O, et al. Front Aging Neurosci. 2014 Jul 30;6:190. doi: 10.3389/fnagi.2014.00190. eCollection 2014. Front Aging Neurosci. 2014. PMID: 25126078 Free PMC article.
The greatest risk factor for Alzheimer's disease (AD) is age, and changes in the ageing nervous system are likely contributors to AD pathology. ...At both the low and high doses tested, lithium rescued the locomotory defects induced by Abeta42, but it …
The greatest risk factor for Alzheimer's disease (AD) is age, and changes in the ageing nervous system are likely contr …
Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease.
Nunes MA, Viel TA, Buck HS. Nunes MA, et al. Curr Alzheimer Res. 2013 Jan;10(1):104-7. doi: 10.2174/1567205011310010014. Curr Alzheimer Res. 2013. PMID: 22746245 Clinical Trial.
Following the same rationale, a group just found that lithium has disease-modifying properties in amnestic mild cognitive impairment with potential clinical implications for the prevention of Alzheimer's Disease (AD) when a dose ranging from 150 …
Following the same rationale, a group just found that lithium has disease-modifying properties in amnestic mild cognitive impa …
Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease.
Mury FB, da Silva WC, Barbosa NR, Mendes CT, Bonini JS, Sarkis JE, Cammarota M, Izquierdo I, Gattaz WF, Dias-Neto E. Mury FB, et al. Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):607-18. doi: 10.1007/s00406-015-0665-2. Epub 2015 Dec 11. Eur Arch Psychiatry Clin Neurosci. 2016. PMID: 26661385
Moreover, cognitive decline and memory deficits showed to be reduced in animal models after lithium treatment, prompting us to evaluate possible links between Pla2, lithium and memory. ...Our data pointed to a significant perdurability of long-term memory, which cor …
Moreover, cognitive decline and memory deficits showed to be reduced in animal models after lithium treatment, prompting us to evalua …
Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model.
Zhao L, Gong N, Liu M, Pan X, Sang S, Sun X, Yu Z, Fang Q, Zhao N, Fei G, Jin L, Zhong C, Xu T. Zhao L, et al. Neurobiol Aging. 2014 Dec;35(12):2736-2745. doi: 10.1016/j.neurobiolaging.2014.06.003. Epub 2014 Jun 14. Neurobiol Aging. 2014. PMID: 25018109 Free article.
Alzheimer's disease (AD) is a complicated, neurodegenerative disorder involving multifactorial pathogeneses and still lacks effective clinical treatment. Recent studies show that lithium exerts disease-modifying effects against AD. However, the …
Alzheimer's disease (AD) is a complicated, neurodegenerative disorder involving multifactorial pathogeneses and still l …
Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis.
Wilson EN, Do Carmo S, Iulita MF, Hall H, Austin GL, Jia DT, Malcolm JC, Foret MK, Marks AR, Butterfield DA, Cuello AC. Wilson EN, et al. Curr Alzheimer Res. 2018;15(13):1220-1230. doi: 10.2174/1567205015666180904154446. Curr Alzheimer Res. 2018. PMID: 30182855
BACKGROUND: Microdose lithium is protective against Alzheimer's disease (AD), although the precise mechanisms through which its protective effects are conferred remain unclear. ...CONCLUSION: These results suggest that NP03 may function to slow the AD- …
BACKGROUND: Microdose lithium is protective against Alzheimer's disease (AD), although the precise mechanisms th …
Autophagy in trimethyltin-induced neurodegeneration.
Pompili E, Fabrizi C, Fumagalli L, Fornai F. Pompili E, et al. J Neural Transm (Vienna). 2020 Jul;127(7):987-998. doi: 10.1007/s00702-020-02210-1. Epub 2020 May 25. J Neural Transm (Vienna). 2020. PMID: 32451631 Review.
TMT is considered a useful tool to study the molecular mechanisms occurring in human neurodegenerative diseases such as Alzheimer's disease and temporal lobe epilepsy. This is also relevant in the field of environmental safety, since organotin compounds are u …
TMT is considered a useful tool to study the molecular mechanisms occurring in human neurodegenerative diseases such as Alzheimer' …
Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
Kurz C, Stöckl L, Schrurs I, Suridjan I, Gürsel SÜ, Bittner T, Jethwa A, Perneczky R. Kurz C, et al. J Neurochem. 2023 Apr;165(1):95-105. doi: 10.1111/jnc.15757. Epub 2023 Jan 23. J Neurochem. 2023. PMID: 36625424 Free article.
An unmet need exists for reliable plasma biomarkers of amyloid pathology, in the clinical laboratory setting, to streamline diagnosis of Alzheimer's disease (AD). For routine clinical use, a biomarker must provide robust and reliable results under pre-analyti …
An unmet need exists for reliable plasma biomarkers of amyloid pathology, in the clinical laboratory setting, to streamline diagnosis of …
Targeting glycogen synthase kinase-3beta for Alzheimer's disease: Recent advances and future Prospects.
Cheng Z, Han T, Yao J, Wang K, Dong X, Yu F, Huang H, Han M, Liao Q, He S, Lyu W, Li Q. Cheng Z, et al. Eur J Med Chem. 2024 Feb 5;265:116065. doi: 10.1016/j.ejmech.2023.116065. Epub 2023 Dec 20. Eur J Med Chem. 2024. PMID: 38160617 Review.
Senile plaques induced by beta-amyloid (Abeta) abnormal aggregation and neurofibrillary tangles (NFT) caused by tau hyperphosphorylation are important pathological manifestations of Alzheimer's disease (AD). Glycogen synthase kinase-3 (GSK-3) is a conserved k …
Senile plaques induced by beta-amyloid (Abeta) abnormal aggregation and neurofibrillary tangles (NFT) caused by tau hyperphosphorylation are …
Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders?
Morlet É, Hozer F, Costemale-Lacoste JF. Morlet É, et al. Geriatr Psychol Neuropsychiatr Vieil. 2018 Mar 1;16(1):78-86. doi: 10.1684/pnv.2017.0718. Geriatr Psychol Neuropsychiatr Vieil. 2018. PMID: 29400298 Review. English.
Results were found concerning Alzheimer's disease and related dementias, Huntington's disease, amyotrophic lateral sclerosis and spino-cerebellar ataxia. Lithium exposure showed a potential neuroprotective effect in studies on psychiatric popula …
Results were found concerning Alzheimer's disease and related dementias, Huntington's disease, amyotrophic later …
Lithium Intoxication as a cause of reversible dementia mimicking FDG PET features of Alzheimer's disease.
Mecê AM, Abreu VC, Lamas GM, Tacla RDR, Minekawa TB, Ramos CD, Balthazar MLF. Mecê AM, et al. Dement Neuropsychol. 2022 Apr-Jun;16(2):249-252. doi: 10.1590/1980-5764-DN-2021-0105. Epub 2022 Apr 29. Dement Neuropsychol. 2022. PMID: 35720658 Free PMC article.
Clinical suspicion, laboratory confirmation, and drug interruption are key points in the management of lithium intoxication. We described a 66-year-old female patient under treatment with lithium who developed an RPD associated with parkinsonian symptoms. (18)F-fluo …
Clinical suspicion, laboratory confirmation, and drug interruption are key points in the management of lithium intoxication. We descr …
Experimental data on lithium salts: From neuroprotection to multi-organ complications.
Kakhki S, Ahmadi-Soleimani SM. Kakhki S, et al. Life Sci. 2022 Oct 1;306:120811. doi: 10.1016/j.lfs.2022.120811. Epub 2022 Jul 16. Life Sci. 2022. PMID: 35850248 Review.
It is also known to protect the brain against neurodegenerative processes such as Alzheimer's disease. Despite the mentioned merits, recent studies have revealed that high dose or prolonged lithium intake deteriorate the function of multiple key organs …
It is also known to protect the brain against neurodegenerative processes such as Alzheimer's disease. Despite the ment …
Lithium Benzoate Exerts Neuroprotective Effect by Improving Mitochondrial Function, Attenuating Reactive Oxygen Species, and Protecting Cognition and Memory in an Animal Model of Alzheimer's Disease.
Lu LP, Chang WH, Huang JJ, Tan P, Tsai GE. Lu LP, et al. J Alzheimers Dis Rep. 2022 Sep 20;6(1):557-575. doi: 10.3233/ADR-220025. eCollection 2022. J Alzheimers Dis Rep. 2022. PMID: 36275418 Free PMC article.
BACKGROUND: Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting many cellular pathways, including protein aggregation, mitochondrial dysfunction, oxidative stress (OS), and neuroinflammation. Currently, no effective treatme …
BACKGROUND: Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting many cellular pathw …
Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease.
Nunes MA, Schöwe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SI, Balthazar J, Albuquerque MS, Caetano AL, Viel TA, Buck HS. Nunes MA, et al. PLoS One. 2015 Nov 25;10(11):e0142267. doi: 10.1371/journal.pone.0142267. eCollection 2015. PLoS One. 2015. PMID: 26605788 Free PMC article.
Recently, our group showed that treatment with microdose lithium stabilized the cognitive deficits observed in Alzheimer's disease (AD) patients. ...It is suitable to conclude that these data support the use of microdose lithium in the preventio …
Recently, our group showed that treatment with microdose lithium stabilized the cognitive deficits observed in Alzheimer's …
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
Ahn KC, Learman CR, Baker GB, Weaver CL, Chung PS, Kim HG, Song MS. Ahn KC, et al. J Korean Med Sci. 2019 Dec 2;34(46):e297. doi: 10.3346/jkms.2019.34.e297. J Korean Med Sci. 2019. PMID: 31779058 Free PMC article. Review.
Accumulated evidence suggests that sporadic cases of Alzheimer's disease (AD) make up more than 95% of total AD patients, and diabetes has been implicated as a strong risk factor for the development of AD. ...
Accumulated evidence suggests that sporadic cases of Alzheimer's disease (AD) make up more than 95% of total AD patient …
Recent developments in geriatric psychopharmacology.
Aftab A, Lam JA, Liu F, Ghosh A, Sajatovic M. Aftab A, et al. Expert Rev Clin Pharmacol. 2021 Mar;14(3):341-355. doi: 10.1080/17512433.2021.1882848. Epub 2021 Feb 5. Expert Rev Clin Pharmacol. 2021. PMID: 33499693 Review.
Recent developments relevant to geriatric psychiatry have focused on Alzheimer's disease (AD), severe/refractory depression, and cancer/end of life care. ...Promising pharmaceuticals for neuropsychiatric symptoms of dementia include pimavanserin, brexpiprazol …
Recent developments relevant to geriatric psychiatry have focused on Alzheimer's disease (AD), severe/refractory depres …
Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease.
Yeh HL, Tsai SJ. Yeh HL, et al. Med Hypotheses. 2008 Dec;71(6):948-51. doi: 10.1016/j.mehy.2008.03.049. Epub 2008 Aug 28. Med Hypotheses. 2008. PMID: 18760542
Alzheimer's disease (AD) is the most common form of dementia among older people. Presenile familial AD (FAD) and sporadic Alzheimer's disease (SAD) have identical brain lesions, containing senile plaques with beta-amyloid (Abeta) peptide …
Alzheimer's disease (AD) is the most common form of dementia among older people. Presenile familial AD (FAD) and sporad …
Chronic Lithium Treatment Increases Telomere Length in Parietal Cortex and Hippocampus of Triple-Transgenic Alzheimer's Disease Mice.
Cardillo GM, De-Paula VJR, Ikenaga EH, Costa LR, Catanozi S, Schaeffer EL, Gattaz WF, Kerr DS, Forlenza OV. Cardillo GM, et al. J Alzheimers Dis. 2018;63(1):93-101. doi: 10.3233/JAD-170838. J Alzheimers Dis. 2018. PMID: 29614649
Telomere length (TL) is a biomarker of cell aging, and its shortening has been linked to several age-related diseases. In Alzheimer's disease (AD), telomere shortening has been associated with neuroinflammation and oxidative stress. ...Our findings suggest th …
Telomere length (TL) is a biomarker of cell aging, and its shortening has been linked to several age-related diseases. In Alzheimer' …
An Overview of the Neurotrophic and Neuroprotective Properties of the Psychoactive Drug Lithium as an Autophagy Modulator in Neurodegenerative Conditions.
Singh A, Arora S, Chavan M, Shahbaz S, Jabeen H. Singh A, et al. Cureus. 2023 Aug 24;15(8):e44051. doi: 10.7759/cureus.44051. eCollection 2023 Aug. Cureus. 2023. PMID: 37746513 Free PMC article. Review.
For both short-term and long-term treatment of bipolar disorder, lithium is a prototypical mood stabilizer. Lithium's neuroprotective properties were revealed by cumulative translational research, which opened the door to reforming the chemical as a treatment …
For both short-term and long-term treatment of bipolar disorder, lithium is a prototypical mood stabilizer. Lithium's n …
Special Issue: "Molecules against Alzheimer".
Decker M, Muñoz-Torrero D. Decker M, et al. Molecules. 2016 Dec 16;21(12):1736. doi: 10.3390/molecules21121736. Molecules. 2016. PMID: 27999295 Free PMC article.
This Special Issue, entitled "Molecules against Alzheimer", gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzh …
This Special Issue, entitled "Molecules against Alzheimer", gathers a number of original articles, short communications, and review a …
Antiviral, immunomodulatory, and neuroprotective effect of lithium.
Rybakowski JK. Rybakowski JK. J Integr Neurosci. 2022 Mar 23;21(2):68. doi: 10.31083/j.jin2102068. J Integr Neurosci. 2022. PMID: 35364656 Free article. Review.
The goal of the review is to describe the experimental and clinical studies on the last three properties of lithium. Antiviral effects of lithium pertain mostly to DNA viruses, especially herpes viruses. ...On the clinical level, some preventive action against demen …
The goal of the review is to describe the experimental and clinical studies on the last three properties of lithium. Antiviral effect …
Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment.
Fessel WJ. Fessel WJ. Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17. Am J Alzheimers Dis Other Demen. 2017. PMID: 28423937 Free PMC article. Review.
The pathogenesis of Alzheimer's disease involves multiple pathways that, at the macrolevel, include decreased proliferation plus increased loss affecting neurons, astrocytes, and capillaries and, at the subcellular level, involve several elements: amyloid/amy …
The pathogenesis of Alzheimer's disease involves multiple pathways that, at the macrolevel, include decreased prolifera …
Stem cell therapy for Alzheimer's disease.
Abdel-Salam OM. Abdel-Salam OM. CNS Neurol Disord Drug Targets. 2011 Jun;10(4):459-85. doi: 10.2174/187152711795563976. CNS Neurol Disord Drug Targets. 2011. PMID: 21495961 Review.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder which impairs the memory and intellectual abilities of the affected individuals. ...Studies in patients with AD indicated decreased hippocampal volume derived by neurodegeneration. Intriguin …
Alzheimer's disease (AD) is a progressive neurodegenerative disorder which impairs the memory and intellectual abilitie …
Lithium beyond psychiatric indications: the reincarnation of a new old drug.
Haupt M, Bähr M, Doeppner TR. Haupt M, et al. Neural Regen Res. 2021 Dec;16(12):2383-2387. doi: 10.4103/1673-5374.313015. Neural Regen Res. 2021. PMID: 33907010 Free PMC article. Review.
As a matter of fact, preclinical work reports both acute and long-term neuroprotection in distinct neurological disease models such as Parkinson's disease, traumatic brain injury, Alzheimer's disease, and ischemic stroke. Lithium treatmen …
As a matter of fact, preclinical work reports both acute and long-term neuroprotection in distinct neurological disease models such a …
Examining the Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-Adjusted Alzheimer's Disease Mortality in Texas.
Fajardo VA, Fajardo VA, LeBlanc PJ, MacPherson REK. Fajardo VA, et al. J Alzheimers Dis. 2018;61(1):425-434. doi: 10.3233/JAD-170744. J Alzheimers Dis. 2018. PMID: 29103043 Free PMC article.
BACKGROUND: Alzheimer's disease (AD) mortality rates have steadily increased over time. Lithium, the current gold standard treatment for bipolar disorder, can exert neuroprotective effects against AD. ...
BACKGROUND: Alzheimer's disease (AD) mortality rates have steadily increased over time. Lithium, the current gol …
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.
Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C. Leyhe T, et al. J Alzheimers Dis. 2009;16(3):649-56. doi: 10.3233/JAD-2009-1004. J Alzheimers Dis. 2009. PMID: 19276559 Clinical Trial.
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease (AD). ...Diminution of cognitive impairment was inversely correlated with lithium serum concentration. Upregulation of BDNF might …
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease …
Is lithium a neuroprotective agent?
Vo TM, Perry P, Ellerby M, Bohnert K. Vo TM, et al. Ann Clin Psychiatry. 2015 Feb;27(1):49-54. Ann Clin Psychiatry. 2015. PMID: 25696782 Review.
However, the medical literature suggests that lithium may have an indication as a neuroprotective agent. METHODS: This review discusses the pharmacologic activity and potential effectiveness of lithium in the context of Alzheimer disease (AD) and Parki …
However, the medical literature suggests that lithium may have an indication as a neuroprotective agent. METHODS: This review discuss …
Increased Prevalence of Obesity/Type 2 Diabetes and Lower Levels of Lithium in Rural Texas Counties May Explain Greater Alzheimer's Disease Risk.
Baranowski BJ, Hayward GC, Fajardo VA, MacPherson REK. Baranowski BJ, et al. J Alzheimers Dis. 2018;64(1):303-308. doi: 10.3233/JAD-171150. J Alzheimers Dis. 2018. PMID: 29865052
BACKGROUND/OBJECTIVE: To compare Alzheimer's disease (AD) mortality rates and coinciding risk factors in rural and urban Texas populations. ...Further analysis controlling for physical inactivity, education, and trace lithium concentrations results in …
BACKGROUND/OBJECTIVE: To compare Alzheimer's disease (AD) mortality rates and coinciding risk factors in rural and urba …
Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs.
Fessel J. Fessel J. Alzheimers Dement (N Y). 2019 Nov 16;5:780-788. doi: 10.1016/j.trci.2019.09.019. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31763432 Free PMC article. Review.
Several hundred clinical trials of initially promising drugs have failed to produce meaningful clinical improvement of Alzheimer's disease (AD), which is probably because there are at least 25 biochemical pathways known to be aberrant that underpin the dis …
Several hundred clinical trials of initially promising drugs have failed to produce meaningful clinical improvement of Alzheimer's …
Molecular Insights to the Wnt Signaling During Alzheimer's Disorder: a Potential Target for Therapeutic Interventions.
Nagu P, Sharma V, Behl T, Pathan AKA, Mehta V. Nagu P, et al. J Mol Neurosci. 2022 Apr;72(4):679-690. doi: 10.1007/s12031-021-01940-5. Epub 2022 Jan 7. J Mol Neurosci. 2022. PMID: 34997460 Review.
Impaired Wnt signaling pathways are associated with enhanced levels of amyloid-beta, reduced beta-catenin levels, and increased expression of GSK-3beta enzyme, suggesting its direct association with the pathogenesis of Alzheimer's disorder (AD). These findings are c …
Impaired Wnt signaling pathways are associated with enhanced levels of amyloid-beta, reduced beta-catenin levels, and increased expression o …
Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches.
Corrêa-Velloso JC, Gonçalves MC, Naaldijk Y, Oliveira-Giacomelli Á, Pillat MM, Ulrich H. Corrêa-Velloso JC, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt A):34-53. doi: 10.1016/j.pnpbp.2017.04.033. Epub 2017 May 3. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 28476640 Review.
We review here common mechanisms underlying the comorbidity of Bipolar Disorders and Alzheimer's Disease, such as aberrant neurogenesis and neurotoxicity, reporting current therapeutic approaches. The understanding of these mechanisms precedes stem cell-based …
We review here common mechanisms underlying the comorbidity of Bipolar Disorders and Alzheimer's Disease, such as aberr …
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease.
Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, Leyhe T. Straten G, et al. Curr Alzheimer Res. 2011 Dec;8(8):853-9. doi: 10.2174/156720511798192754. Curr Alzheimer Res. 2011. PMID: 21875410 Clinical Trial.
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease (AD). ...In another previous study we have shown that glial cell line-derived neurotrophic factor (GDNF) levels in CSF of patients with …
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease …
Lithium alters expression of RNAs in a type-specific manner in differentiated human neuroblastoma neuronal cultures, including specific genes involved in Alzheimer's disease.
Maloney B, Balaraman Y, Liu Y, Chopra N, Edenberg HJ, Kelsoe J, Nurnberger JI, Lahiri DK. Maloney B, et al. Sci Rep. 2019 Dec 4;9(1):18261. doi: 10.1038/s41598-019-54076-3. Sci Rep. 2019. PMID: 31797941 Free PMC article.
It is currently under investigation for multiple nervous system disorders, including Alzheimer's disease (AD). While perturbation of RNA levels by Li has been previously reported, its effects on the whole transcriptome has been given little attention. ...Nota …
It is currently under investigation for multiple nervous system disorders, including Alzheimer's disease (AD). While pe …
Possible lithium-induced extrapyramidal effects in Alzheimer's disease.
Randels PM, Marco LA, Hanspal NS, Robinson B. Randels PM, et al. Hillside J Clin Psychiatry. 1984;6(1):117-21. Hillside J Clin Psychiatry. 1984. PMID: 6571454
Extrapyramidal symptomatology has previously been reported in patients on long-term lithium maintenance. This report emphasizes that, in the presence of organic mental disorder, even brief treatment with lithium may induce severe extrapyramidal signs. Furthermore, t …
Extrapyramidal symptomatology has previously been reported in patients on long-term lithium maintenance. This report emphasizes that, …
Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art.
Medić B, Stojanović M, Stimec BV, Divac N, Vujović KS, Stojanović R, Čolović M, Krstić D, Prostran M. Medić B, et al. Curr Med Chem. 2020;27(3):337-351. doi: 10.2174/0929867325666180904124733. Curr Med Chem. 2020. PMID: 30182841 Review.
Lithium is the smallest monovalent cation with many different biological effects. ...Beside, lithium showed some protective effects in neurological diseases including acute neural injury, chronic degenerative conditions, Alzheimer's disease as w …
Lithium is the smallest monovalent cation with many different biological effects. ...Beside, lithium showed some protective ef …
P2C-Type ATPases and Their Regulation.
Retamales-Ortega R, Vio CP, Inestrosa NC. Retamales-Ortega R, et al. Mol Neurobiol. 2016 Mar;53(2):1343-1354. doi: 10.1007/s12035-014-9076-z. Epub 2015 Jan 29. Mol Neurobiol. 2016. PMID: 25631710 Review.
Na(+)/K(+)-ATPase has become a center of attention ever since it was proposed that it might play a crucial role in neurological disorders such as bipolar disorder, mania, depression, familial hemiplegic migraine, rapid-onset dystonia parkinsonism, chronic stress, epileptogenesis, …
Na(+)/K(+)-ATPase has become a center of attention ever since it was proposed that it might play a crucial role in neurological disorders su …
526 results